Does Insurance Cover Ozempic?
Ozempic, Wegovy, Mounjaro, Zepbound — the GLP-1 medications behind the biggest pharmacy story of the decade. Coverage depends entirely on why you’re prescribed it. Type 2 diabetes? Usually covered. Weight loss? Much harder. Here’s the honest breakdown of insurance reality, the prior authorization process, and the legitimate ways to bring the cost down — including manufacturer self-pay prices that start at $149/month for the lowest-dose tablets (as of October 2026).
Ozempic coverage depends almost entirely on diagnosis. When prescribed for Type 2 diabetes — the FDA-approved indication — Ozempic is covered by most ACA Marketplace plans, employer plans, and Medicare Part D, typically with prior authorization. When prescribed off-label for weight loss, most plans deny coverage and direct patients toward Wegovy (the same drug, FDA-approved specifically for weight management). Wegovy coverage for weight loss varies dramatically — many employer plans exclude it, many ACA plans don’t cover it, and Medicare Part D plans still don’t cover GLP-1s purely for weight loss, although a temporary CMS program (the Medicare GLP-1 Bridge) now offers some of them to eligible enrollees for a $50 monthly copay. Without insurance, the manufacturers’ listed self-pay prices run roughly $149–$699/month depending on the drug and dose (as of October 2026). Patient assistance programs, manufacturer savings cards, and Medicaid in some states can lower the cost further for those who qualify.
Last updated:
1. The GLP-1 drug landscape
“GLP-1 agonists” are a class of medications originally developed for Type 2 diabetes that turned out to have significant weight loss effects. The result: a confusing landscape of brand names that are sometimes the same drug for different uses.
| Brand | Generic | FDA approval | Manufacturer |
|---|---|---|---|
| Ozempic | Semaglutide (injection; tablets also sold) | Type 2 diabetes | Novo Nordisk |
| Wegovy | Semaglutide (injection or tablet) | Chronic weight management | Novo Nordisk |
| Rybelsus | Semaglutide (oral pill) | Type 2 diabetes | Novo Nordisk |
| Mounjaro | Tirzepatide (injectable) | Type 2 diabetes | Eli Lilly |
| Zepbound | Tirzepatide (injectable) | Chronic weight management, sleep apnea | Eli Lilly |
| Saxenda | Liraglutide (injectable) | Chronic weight management | Novo Nordisk |
| Victoza | Liraglutide (injectable) | Type 2 diabetes | Novo Nordisk |
The pattern: same drug, different brands
Ozempic and Wegovy contain the same active ingredient (semaglutide) at similar doses. Mounjaro and Zepbound contain the same active ingredient (tirzepatide). The drugs are branded separately so manufacturers can list them at different prices, with different prior authorization rules, and with FDA approval limited to a specific use. This dual-branding is exactly why coverage gets so complicated.
2. Two paths: diabetes coverage vs weight loss coverage
The single most important factor in GLP-1 coverage is what your prescription is treating.
Path 1: Type 2 diabetes (typically covered)
If you have a documented Type 2 diabetes diagnosis and your physician prescribes Ozempic, Mounjaro, Rybelsus, or Victoza, most plans cover it with prior authorization. Typical coverage requirements:
- Confirmed T2D diagnosis (A1C 6.5%+ or established history)
- Documentation of prior treatment attempts (often metformin first-line)
- BMI documentation (sometimes required)
- No contraindicated medical conditions
Once approved, copays vary by plan and tier:
- Preferred-brand tier: usually a flat monthly copay
- Non-preferred brand tier: a higher copay
- Specialty tier: often coinsurance (a percentage of the drug’s price), which can be expensive
Check your plan’s formulary and Summary of Benefits for the exact amount at your dose.
Path 2: Weight loss (much harder)
When prescribed for weight management without a T2D diagnosis, coverage is dramatically more restrictive:
- Many employer plans exclude GLP-1s for weight loss, often citing cost
- Many ACA Marketplace plans don’t cover weight loss medications at all
- Medicare Part D plans still don’t cover GLP-1s purely for weight loss; a temporary CMS demonstration, the Medicare GLP-1 Bridge, runs from July 1, 2026 through December 31, 2027 (see section 5)
- State Medicaid programs vary — some cover Wegovy/Zepbound for weight management with criteria; others don’t
For weight loss-specific brands (Wegovy, Zepbound, Saxenda), when coverage is available, plans usually tie it to the drug’s FDA-approved use — for Wegovy, adults with obesity, or with overweight plus at least one weight-related health condition (FDA label) — and add their own criteria, which vary by plan:
- A minimum BMI set by the plan, and documentation of any weight-related health condition
- Documented prior weight loss attempts
- Concurrent lifestyle modification program
3. ACA Marketplace coverage reality
The ACA’s 10 Essential Health Benefits include “prescription drugs” but don’t mandate coverage of specific medications. Each state’s benchmark plan determines what drugs are required to be covered, and within that, each plan has its own formulary.
For Type 2 diabetes
Most ACA Marketplace plans cover Ozempic and Mounjaro as Tier 2 or Tier 3 brand-name medications when prescribed for T2D. Prior authorization is very common. Step therapy (try cheaper drugs first) is increasingly common — you may need to try and fail metformin and a sulfonylurea before getting Ozempic approved.
For weight loss
Most ACA Marketplace plans do NOT cover weight loss medications. The federal benchmark plan doesn’t require it, and few states have added it. Some standalone exceptions exist but they’re the minority. If you’re shopping for an ACA plan specifically to get weight loss medications covered, expect disappointment in most markets.
What to check before enrolling
- Pull the plan’s formulary (drug list) and search for “semaglutide,” “tirzepatide,” “Wegovy,” “Zepbound”
- Check what tier the drug is on (Tier 4 = expensive even when covered)
- Note if there are quantity limits, prior auth, or step therapy requirements
- Verify your specific dose/strength is covered
4. Employer plan coverage
Employer plan coverage of GLP-1s has been the central drama of pharmacy benefits in 2024–2026. Many large employers added Wegovy and Zepbound to their formularies in 2023–2024 only to remove or restrict coverage as drug spending exploded.
What’s happened
- Employer pharmacy spending on GLP-1s climbed quickly, pushing many plans to add limits
- Many employers have moved to exclude GLP-1s for weight loss
- Some employers maintain coverage with strict criteria, such as higher BMI thresholds, a documented comorbidity, mandatory lifestyle program participation, and quantity limits
- Self-insured plans have full discretion to include or exclude weight loss drugs (KFF’s 2025 Employer Health Benefits Survey found 80% of covered workers at firms with 200 or more workers are in self-funded plans)
What employers typically still cover
- Ozempic, Mounjaro, Rybelsus, Victoza for confirmed Type 2 diabetes (usually with PA)
- Saxenda for chronic weight management at fewer plans
- Wegovy and Zepbound for weight loss at a shrinking minority of plans, usually with strict criteria
What to do if your employer plan denied coverage
- Verify your plan’s exact formulary policy for the specific drug
- If denied based on diagnosis, talk to your physician about whether T2D criteria can be appropriately documented (only if medically accurate)
- Check if any related conditions covered by the drug (sleep apnea coverage was added to Zepbound in late 2024) apply to you
- Appeal with strong physician documentation if you believe the denial was incorrect
- Explore patient assistance programs as a fallback
5. Medicare and Medicaid coverage
Medicare Part D
Medicare Part D plans cover GLP-1s for Type 2 diabetes, usually with prior authorization. Copays or coinsurance depend on the plan and the drug’s tier.
For weight loss, Part D plans still don’t cover GLP-1s. In April 2025, CMS declined to finalize a proposal that would have added anti-obesity medications to Part D (CMS). Instead, CMS is running a temporary demonstration, the Medicare GLP-1 Bridge: from July 1, 2026 through December 31, 2027, eligible Part D enrollees can get Wegovy (injection or tablet), Zepbound (KwikPen only) or Foundayo (tablet) for a $50 monthly copay, outside the regular Part D benefit (CMS). Ozempic is not on the Bridge list. To qualify you must be 18 or older and have a BMI of 35 or higher, a BMI of 30 or higher with certain heart, blood pressure or kidney conditions, or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease; prior authorization is required. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease aren’t eligible for the Bridge, because their Part D plan may cover a GLP-1 instead (Medicare.gov).
When a GLP-1 is FDA-approved for another condition — such as Wegovy for cardiovascular risk reduction in some adults or Zepbound for obstructive sleep apnea — Part D plans may cover it for that specific use.
Medicaid
State Medicaid programs handle GLP-1 coverage very differently:
- Type 2 diabetes: Generally covered across all state Medicaid programs with PA
- Weight loss: Coverage varies dramatically. A growing number of states cover Wegovy or Zepbound through Medicaid for adults meeting clinical criteria. Many states still don’t. The list is changing — check your state’s most current Medicaid Preferred Drug List.
6. The prior authorization process
Prior authorization (PA) is very common for GLP-1 medications. Understanding the process helps you get approved faster.
How PA works
- Your physician submits a PA request to your insurance/PBM with clinical documentation
- The PBM reviews documentation against the plan’s coverage criteria
- Decision returned within the plan’s deadline; urgent requests are decided faster
- If approved, prescription processes at pharmacy
- If denied, written denial with appeal rights
What documentation strengthens a PA request
- For T2D: Recent A1C results showing diagnosis, prior medication history (metformin trial if applicable), comorbidity documentation
- For weight loss: BMI documentation over time, comorbidity diagnoses with ICD-10 codes, prior weight loss attempts documented, blood pressure/lipid panel showing cardiovascular risk
- Statement of medical necessity from prescriber addressing plan-specific criteria
What gets denials
- Diagnosis doesn’t match drug’s FDA-approved indication
- Missing trials of cheaper therapy (step therapy violation)
- BMI documentation insufficient or below threshold
- Off-label use (Ozempic prescribed for weight loss instead of Wegovy)
- Missing supporting clinical notes
How to appeal a denial
Federal law requires insurers to provide an appeals process. Most appeals can include:
- Internal appeal to the insurance company (you generally have 180 days after the denial to file, per HealthCare.gov)
- External review by an independent organization if internal appeal fails
- Expedited appeals if there’s urgent medical need
Some GLP-1 denials are overturned on appeal when documentation is strengthened. Your physician’s office can typically help with the appeal letter.
7. Cost without insurance
| Medication | Manufacturer self-pay price (monthly, as of October 2026) |
|---|---|
| Ozempic (pen) | $349 for 0.25, 0.5 or 1 mg; $499 for 2 mg. New patients: $199/month for the first 2 fills of 0.25 or 0.5 mg (offer through Dec 31, 2026) |
| Ozempic (tablets) | $149 (1.5 mg), $199 (4 mg), $299 (9 mg) |
| Wegovy (pen) | $349 for 0.25 to 2.4 mg; $399 for Wegovy HD 7.2 mg. New patients: $199/month for the first 2 fills of 0.25 or 0.5 mg (offer through Dec 31, 2026) |
| Wegovy (tablets) | $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) |
| Zepbound (vials or KwikPen) | $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) through LillyDirect if you refill within 45 days; otherwise $499 (7.5 mg) or $699 (10–15 mg) |
| Rybelsus, Mounjaro, Saxenda, Victoza | Not listed here — cash prices vary by pharmacy, so ask your pharmacy or the manufacturer |
These are self-pay prices listed by the manufacturers (NovoCare (Ozempic), NovoCare (Wegovy), LillyDirect); eligibility rules and restrictions apply, and prices change often. Ozempic is FDA-approved for Type 2 diabetes, not weight loss. Retail pharmacy cash prices can differ. Discount cards such as GoodRx and SingleCare, and big-box pharmacy memberships (Costco, Sam’s Club), sometimes lower the price for cash payers.
8. Patient assistance and savings options
If your insurance doesn’t cover the drug, several options can significantly reduce the cash cost:
Manufacturer savings cards
- Novo Nordisk: Ozempic, Wegovy, Rybelsus, Saxenda all have savings cards reducing costs for commercially-insured patients (cards do not apply to Medicare, Medicaid, or other federal programs)
- Eli Lilly: Mounjaro and Zepbound savings cards similarly available for commercially-insured patients
These cards can lower your out-of-pocket cost if you’re eligible; terms and savings limits vary by card. Critically: the card requires commercial insurance coverage to work. If your insurance doesn’t cover the drug at all, the savings card doesn’t apply.
Patient Assistance Programs (PAPs)
Both Novo Nordisk and Eli Lilly run Patient Assistance Programs for low-income patients without insurance or with significant coverage gaps. Income limits and other eligibility rules apply, and assistance can provide medication at no cost or significantly reduced cost. Applications require documentation of income, residency, and lack of coverage.
LillyDirect (Lilly’s direct-to-patient program)
Eli Lilly sells Zepbound vials and KwikPens at self-pay prices through LillyDirect — as of October 2026, $299–$449 a month with an on-time refill (see the table above). Verify current pricing at the official LillyDirect site.
Wegovy direct from Novo Nordisk
Novo Nordisk sells Wegovy through NovoCare Pharmacy for self-pay patients — as of October 2026, $349 a month for most pen doses, with tablets from $149 (see the table above). Verify current pricing and eligibility at the official NovoCare site.
Switch insurance plans during Open Enrollment
If your current plan doesn’t cover your medication, switching to one that does during Open Enrollment (November 1, 2026 – January 15, 2027 on HealthCare.gov) can dramatically change your cost. Verify the new plan’s formulary explicitly covers your medication before switching.
Telehealth platforms
Several telehealth companies (Ro, Hims, Sequence/Weight Watchers, others) offer prescription evaluation and access to brand-name or some compounded GLP-1s. Costs vary widely; quality of medical oversight varies. Patients should verify the prescribing clinician is properly licensed and that medication sources are FDA-regulated.
Sources
- HealthCare.gov: Getting prescription medications — how to check a plan’s formulary (approved drug list) before you fill a prescription.
- HealthCare.gov: What Marketplace plans cover — prescription drugs are one of the 10 essential health benefits every Marketplace plan covers.
- HealthCare.gov: How to appeal an insurance company decision — your right to an internal appeal and an independent external review.
- HealthCare.gov: Dates and deadlines — Open Enrollment runs November 1 to January 15.
- HealthCare.gov: Internal appeals — file within 180 days (6 months) of a claim denial.
- CMS: Medicare GLP-1 Bridge — temporary demonstration, July 1, 2026 to December 31, 2027, with a $50 monthly copay.
- Medicare.gov: Weight loss drugs — which GLP-1s the Bridge covers and who qualifies.
- CMS: Contract Year 2026 final rule fact sheet — Part D coverage of anti-obesity medications was not finalized.
- NovoCare: Ozempic self-pay pricing and Wegovy self-pay pricing — manufacturer prices, checked October 2026.
- LillyDirect: Zepbound self-pay pricing — manufacturer prices, checked October 2026.
- FDA: Policies for compounders as GLP-1 supply stabilizes — shortage resolution and compounding enforcement dates.
- FDA: Wegovy prescribing information (PDF) — approved uses, including chronic weight management in adults with obesity, or overweight plus a weight-related condition.
- KFF: 2025 Employer Health Benefits Survey — share of covered workers in self-funded plans.
Frequently asked questions
Related guides
Find a Plan That Covers Your Medication.
A FreedInsure advisor verifies which Marketplace plans cover your specific GLP-1, at what tier — before you enroll. No fee for our help.
Check My Coverage →